|
Clinical outcome
|
Total
|
Age group
|
|---|
|
Initially selected
|
122
|
28 ≤ 5 years
|
94 > 5 years
|
|
Number of patients: n
|
|
PCR uncorrected responses
| | | |
|
Withdrawn + Lost, n (%)
|
19 (15.6)
|
7 (25)
|
12 (12.8)
|
|
Eligible; n (%)
|
103 (100)
|
21 (20.4)
|
82 (79.6)
|
|
Global failure; n (%)
|
10 (9.7)
|
5 (23.8)
|
5 (6.1)
|
|
ETF; n (%)
|
1 (1 %)
|
1 (4.8)
|
0
|
|
LCF; n (%)
|
1 (1)
|
0
|
1 (1.2)
|
|
LPF; n (%)
|
8 (7.8)
|
4 (19)
|
4 (4.9)
|
|
ACPR; n (%)
|
93 (90.3)
|
16 (76.2)
|
77 (94)
|
|
PCR corrected responses
|
|
Eligible; n (%)
|
103 (100)
|
21 (20.4)
|
82 (78.6)
|
|
Global Failure; n (%)
|
9 (8.7)
|
5 (24)
|
4 (5)
|
|
ACPR; n (%)
|
94 (91.2)
|
16 (76)
|
78 (95)
|
|
Recrudescence; n (%)
|
2 (1.9)
|
1 (4.8)
|
1 (1.2)
|
|
Reinfection; n (%)
|
1 (1)
|
0
|
1 (1.2)
|
-
PCR polymerase chain reaction, n number of patients, ACPR adequate clinical and parasitological response, ETF early treatment failure, LTF late treatment failure
